PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Analyze analyst forecasts for the company and compare them with competitors.
1.01M
No peer data available for comparison.
-202.40K
No peer data available for comparison.
-1.35
No peer data available for comparison.
-35.97M
No peer data available for comparison.
-202.40K
No peer data available for comparison.
37.50M
No peer data available for comparison.
Analyze DCF forecasts for the company and compare them with competitors.
81.00K
Better than MDGL's revenue of 0.00.
-92.14%
Worse than MDGL's revenue growth rate of 0.00%.
-51.13M
Better than MDGL's ebitda of -379.97M.
-63123.46%
Worse than MDGL's ebitda margin of 100.00%.
-51.92M
Better than MDGL's ebit of -380.50M.
-64098.77%
Worse than MDGL's ebit margin of 100.00%.
790.00K
Worse than MDGL's depreciation of 527.00K.
76.68M
Worse than MDGL's total cash of 634.13M.
94662.96%
Better than MDGL's cash as percentage of revenue of 100.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
7.95M
Better than MDGL's accounts payable of 28.04M.
9818.52%
Worse than MDGL's payables as percentage of revenue of 100.00%.
-153.00K
Worse than MDGL's capital expenditure of -1.48M.
-188.89%
Better than MDGL's capex as percentage of revenue of 100.00%.
4.99%
Better than MDGL's weighted average cost of capital (wacc) of 5.15%.
5.02%
Worse than MDGL's cost of equity of 5.01%.
4.08%
Better than MDGL's cost of debt of 12.27%.
-0.23
Worse than MDGL's beta of -0.92.
30.07M
Worse than MDGL's diluted shares outstanding of 21.27M.
1.57M
Better than MDGL's total debt of 119.57M.
49.31M
Worse than MDGL's total equity of 6.18B.
50.89M
Worse than MDGL's total capital of 6.30B.
3.09%
Worse than MDGL's debt weighting of 1.90%.
96.91%
Worse than MDGL's equity weighting of 98.10%.
-51.92M
Better than MDGL's ebiat of -380.50M.
-53.46M
Better than MDGL's unlevered free cash flow of -377.24M.
2.00%
Equal to MDGL's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Better than MDGL's net debt of 19.55M.
71.33M
Worse than MDGL's equity value of 7.30B.
2.37
Worse than MDGL's equity value per share of 343.00.
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.